Brain and behavior correlates of prenatal cannabis exposure

产前大麻暴露的大脑和行为相关性

• 批准号: 10734717
• 负责人: STEPHEN R DAGER
• 金额: $ 69.61万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-07-15 至 2028-05-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10734717
• 关键词: ATOD; Affect; Age; Age Months; Alcohols; Amygdaloid structure; Animal Experimentation; Animals; Antiemetics; Anxiety; Attention; Behavior; Behavioral; Binding; Biological Assay; Birth; Birth Weight; Brain; Brain imaging; Brain region; COVID-19 pandemic; Cannabidiol; Cannabinoids; Cannabis; Cell Adhesion Molecules; Cerebellum; Complementary and alternative medicine; Conceptions; Conscious; Consumption; Data; Development; Diffusion Magnetic Resonance Imaging; Disease; Dopamine D2 Receptor; Dose; Early Diagnosis; Educational Status; Endocannabinoids; Enrollment; Evaluation; Exclusion Criteria; Exhibits; Female; First Pregnancy Trimester; Frequencies; Functional Magnetic Resonance Imaging; Goals; Growth; Head circumference; Health; Health Benefit; Human; Illicit Drugs; Infant; Influentials; Label; Legal; Legal Status; Length; Magnetic Resonance Imaging; Measures; Medicine; Memory; Modernization; Monitor; Mothers; Multimodal Imaging; Nausea and Vomiting; Neonatal; Neurodevelopmental Disorder; Neuropsychology; Newborn Infant; Odors; Outcome; Outcomes Research; Pacific Northwest; Participant; Pathway interactions; Patient Self-Report; Perception; Persons; Pharmacologic Substance; Placenta; Population; Pregnancy; Pregnant Women; Product Labeling; Property; Prospective Studies; Protocols documentation; Psychotropic Drugs; Recreation; Regulation; Reporting; Research; Risk; Second Pregnancy Trimester; Sex Differences; Signal Transduction; Sleep; Stimulus; Structure; System; Testing; Tetrahydrocannabinol; Third Pregnancy Trimester; Time; Tobacco; Update; Urine; Visit; Washington; Woman; Work; adverse outcome; autism spectrum disorder; behavior measurement; behavioral outcome; brain dysfunction; cannabinoid receptor; density; design; drug of abuse; experience; fetal marijuana exposure; follow up assessment; frontal lobe; imaging study; in utero; indexing; infancy; infant outcome; innovation; male; marijuana legalization; marijuana use; marijuana use in pregnancy; marijuana user; maternal marijuana use; motor behavior; myelination; neural; neurobehavior; neurobehavioral; neurodevelopment; pain reduction; polysubstance use; pregnant; prenatal; prenatal exposure; programs; prospective; receptor density; recruit; response; reward processing; symptom management; white matter

Cannabis use during pregnancy has increased substantially, in conjunction with widespread decriminalization/legalization, changing public perceptions about harm, and evidence of cannabis's antiemetic properties. Prior outcomes research on prenatal cannabis exposure is narrow in scope, as these older studies included research participants with polysubstance use (e.g., tobacco, alcohol, illicit drugs). In addition, prior research also likely underestimated potential risks specific to cannabis use during pregnancy because modern strains are 10x more potent than they were 40 years ago. We propose to study neurodevelopment in infants exposed in utero to cannabis using state-of-the-art MRI and behavioral measures. Maternal cannabis use will be measured prospectively using weekly reports validated with labels and urine-based assays. By focusing on infancy, we aim to characterize cannabis-induced brain changes at a time when environmental effects are minimized and are less influential than at older. In addition, we will test the hypothesis that prenatal cannabis exposure is more detrimental to male than females. To test our hypotheses, we will recruit 200 pregnant people (where the mother uses cannabis, but not other drugs, tobacco, or alcohol) and 170 pregnant control participants matched on education level. Infants will receive a neonatal neurobehavioral exam and multi-modal imaging (functional magnetic resonance imaging, diffusion tensor imaging, and structural MRI) under natural sleep at 2-4 weeks-of-age and extensive neuropsychological follow-up assessments at 6 and 18 months. This program of research aims to clarify potential health risks, enabling pregnant people to make better-informed choices surrounding cannabis use during pregnancy.

怀孕期间使用大麻的人数大幅增加，同时， 合法化/合法化，改变公众对危害的看法，以及大麻止吐的证据 特性.先前关于产前大麻暴露的结果研究范围狭窄，因为这些较早的研究 包括使用多种物质的研究参与者（例如，烟草、酒精、非法药物）。此外，事先 研究也可能低估了怀孕期间使用大麻的潜在风险，因为现代 菌株的效力是40年前的10倍我们建议研究婴儿的神经发育 使用最先进的核磁共振成像和行为测量技术在子宫内接触大麻。产妇使用大麻将 使用经标签和尿液检测验证的每周报告进行前瞻性测量。通过关注 在婴儿期，我们的目标是描述大麻引起的大脑变化， 最小化，影响力小于老年人。此外，我们将测试产前大麻 暴露对男性比女性更有害。为了验证我们的假设，我们将招募200名孕妇 人（母亲使用大麻，但不使用其他药物，烟草或酒精）和170名孕妇对照 参与者按教育水平配对。婴儿将接受新生儿神经行为检查和多模式 自然条件下的成像（功能性磁共振成像、扩散张量成像和结构性MRI） 在2-4周龄时进行睡眠，并在6个月和18个月时进行广泛的神经心理随访评估。这 一项研究计划旨在澄清潜在的健康风险，使孕妇能够更好地了解情况。 在怀孕期间使用大麻的选择